Bernard A Fox Ph D
About
Bernard A Fox Ph D is from Portland, Oregon, United States. Bernard works in the following industries: "Biotechnology Research". Bernard is currently Member Board of Directors at Oregon Bioscience Association, located in Portland, Oregon Area. Bernard also works as Ambassador at Society for Immunotherapy of Cancer (SITC), a job Bernard has held since Dec 2012. Another title Bernard currently holds is Chair at World Immunotherapy Council. In Bernard's previous role as a President / Immediate Past President at Society for Immunotherapy of Cancer (SITC), Bernard worked in Milwaukee, WI until Jan 2012. Prior to joining Society for Immunotherapy of Cancer (SITC), Bernard was a Vice President, International Society for Biological Therapy of Cancer (iSBTc, now SITC) at iSBTc and held the position of Vice President, International Society for Biological Therapy of Cancer (iSBTc, now SITC) at Milwaukee, WI. Prior to that, Bernard was a Guest Professor at Xian Jiaotung University, Xian, China from Jan 1999 to Jan 2008. Bernard started working as Guest Professor at Department of Surgery, Ludwig-Maximilians-University in Jan 2001. From Jan 1990 to Jan 1994, Bernard was Surgical Oncology, Department of Surgery at University of Michigan Medical School. Prior to that, Bernard was a Senior Staff Fellow at National Cancer Institute from Jan 1987 to Jan 1990. Bernard started working as Staff Fellow at National Cancer Institute in Jan 1985.
Come check out Bernard A Fox Ph D's email address on finalscout.com, a free professional database with 500 million business professionals and 200 million companies.
Bernard A Fox Ph D's current jobs
The Oregon Bioscience Association provides a unified voice for the Oregon bioscience community by: • Representing the bioscience research-to-commercialization process • Accelerating the growth of the biosciences industry in all parts of Oregon • Enhancing the state's bioscience business and research climate • Helping attract and retain bioscience talent and companies. • Vigorously working to improve the quality of the bioscience workforce • Partnering with government at all levels to achieve its goals
In November, 2017, the World Immunotherapy Council will have an International meeting of their member societies prior to the annual meeting of the Society for Immunotherapy of Cancer (SITC).
UbiVac is a clinical stage immuno-oncology company engaged in the research, development and testing of therapeutic immunotherapy strategies to combat cancer and infectious diseases. UbiVac currently has three immunotherapy platforms under development: 1) Dribbles - DC-targeted vesicles containing more than 100 putative cancer antigens, including "NCI-prioritized" cancer antigens, five TLR agonists and chaperones, 2) Nanoparticles coupled to mosaic HPV E6/E7 peptides and 3) Recombinant, replication-deficient Cytomegalovirus vaccine vector. UbiVac's lead product, a Dribbles "Plus" immunotherapy - DPV-001, recently completed an NCI-funded, randomized multi-center phase II clinical trial (NCT01909752) for adjuvant treatment of patients with definitively treated non-small cell lung cancer (NSCLC). Results showed induction of anti-cancer immunity in all patients and were reported in abstract format at the 2017 ASCO and SITC meetings. UbiVac is also sponsor for a pilot study of DPV-001 in men with advanced prostate cancer (NCT02234921). A clinical trial of DPV-001 + anti-OX40 for patients with advanced triple negative breast cancer, based on strong preclinical studies (Scientific Reports | 6:37558), is expected to open in the second half of 2018. Founded in Portland, OR in 2005 as a spin-out of the Robert W. Franz Cancer Center within the Earle A. Chiles Research Institute, at Providence Portland Medical Center, UbiVac continues to build upon the groundbreaking research being developed in the region. In 2011, UbiVac in cooperation with Oregon Health & Science University created UbiVac-CMV Inc., to license a disabled cytomegalovirus (CMV) vector technology for use as a vaccine. This technology is actively being developed in collaboration with our research partners. www.UbiVac.com
Dr. Fox's goals are to: 1) Develop effective immunotherapies that eliminate tumors in mice, 2) Translate these into patients with cancer, 3) Train next generation of translational investigators. The preclinical group (Dr. Shawn Jensen, David Messenheimer, Tyler Hulett and Zip Feng) use animal models to develop new strategies to augment therapeutic immunotherapy and also defines the mechanisms of T cell-mediated tumor elimination and tumor escape. The translational group (Dr. Sachin Puri, Dr. Christopher Paustian, Tyler Hulett and Zip Feng) transfer these developments into clinical trials, monitor patient’s anti-tumor immune response and develops hypotheses that are returned to the preclinical group for testing in animal models. Current efforts are directed at understanding and characterizing the cellular and humoral anti-tumor immune response. Our group has collaborations with Hong-Ming Hu's lab (EACRI) that are exploring how using autophagasomes can improve cross-presentation of tumor antigens and augment antitumor immunity. We also have a collaboration with Ann Hill’s lab that exploits their observations that vaccination with CMV vectors results in a high percentage of T cells recognizing the CMV vector. By placing tumor/tumor-associated antigens in CMV vectors we are evaluating if this strategy has therapeutic potential. Collaborations with Dominik Ruttinger, Hauke Winter and Natasja van den Engle at the LMU, Munich, Germany are translating discoveries in preclinical models into patients with non small cell lung cancer (NSCLC) and gastric cancer. Collaborations with the FDA are using micro arrays to characterize genes that are overexpressed in circulating tumor cells (CTC) with hopes of using this information to develop the next generation immunotherapies and aid in immunological monitoring and biomarker development. http://oregon.providence.org/our-services/r/robert-w-franz-cancer-research-center/
Dr. Fox is a member of the OHSU graduate faculty. He lectures on cancer immunotherapy to medical students and doctoral students in the program in molecular and cellular biology. Currently Dr. Fox has three graduate students in his lab.
Bernard A Fox Ph D's past jobs
The Society for Immunotherapy of Cancer (SITC) is a 501 (c)(3) non-profit society of medical professionals. Recent advances in immunology and biology have opened up new horizons in the field of cancer therapy, with an upsurge in the integration of new biologic agents into clinical practice. With several high-caliber scientific meetings with a focus on clinical and translational aspects of biologic approaches to cancer treatment and numerous networking opportunities unique to this organization, the Society for Immunotherapy of Cancer (SITC) has developed into the premier destination for interaction and innovation in the cancer biologics community. The goals of SITC are directed towards the rapid dissemination of information in these areas to expedite the safe transfer of both basic and applied research to the clinical setting. Core Purpose To improve cancer patient outcomes by advancing the science, development and application of biological therapy/immunotherapy. Core Values Interaction/Integration - exchange of information and education among basic and translational researchers, clinicians, and young investigators; societies and groups sharing the vision and core values of SITC Innovation - challenge the thinking and seek the best research in the development of biological therapy/immunotherapy Translation - promote the application and understanding of biological therapy/immunotherapy Leadership - define what is new and important and effectively communicate it to all relevant stakeholders
The Society for Immunotherapy of Cancer (SITC), formerly the International Society for Biological Therapy of Cancer (iSBTc). The goals of SITC are directed towards the rapid dissemination of information in these areas to expedite the safe transfer of both basic and applied research to the clinical setting.